Hi [[ session.user.profile.firstName ]]

Medical Research

  • Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
  • Gene synthesis has become a quick and cost-effective way to build your DNA construct for a variety of applications - from protein engineering to bio-based circuit and pathway design. This webinar, presented by Sigma-Aldrich and GENEWIZ will explain the process of gene synthesis, how it compares to traditional cloning techniques, and review some key applications researchers are addressing with synthetic DNA.
  • Key topics to be discussed during the webinar:

    1)The paradox in Pharma
    2)HCPs expectations and behaviours
    3)Pharma Digital Maturity
    4)The Orchestrator rep
    5)How to implement?
  • Vitamin D intake is low among the world’s population, which is a major contributor to clinical deficiency and a persistently high prevalence of low vitamin D status, particularly during wintertime at high (or low) latitude.

    Vitamin D deficiency contributes to the development of nutritional rickets in children and osteomalacia in adults, both seriously debilitating conditions that are completely preventable with an adequate dietary supply of vitamin D and calcium. Regardless of which international recommended intake is selected, the current supply of vitamin D in commonly consumed foods makes it unfeasible for most people to meet their dietary requirements for vitamin D without supplementation.

    Emerging scientific evidence from the EC-funded ODIN project suggests that many foods, including fish, eggs, meats as well as dairy products could be part of a public health strategy for vitamin D deficiency prevention in the population. This would positively impact public health in a cost-effective and inclusive way.

    While most European countries are impacted by suboptimal vitamin D status, Finland is the exception. In 2003, the country introduced a national regulation which includes mandatory fortification of milk and margarine spreads. The population has now achieved a vitamin D status of 75nmol/L. Recently, the Swedish National Food Agency (NFA) proposed to introduce a similar regulation that will go a step further by extending the products subject to mandatory vitamin D fortification.

    *This information is solely for scientific informational purposes only and not intended for marketing and/or sales claims purposes.
  • Vitamin D intake is low among the world’s population, which is a major contributor to clinical deficiency and a persistently high prevalence of low vitamin D status, particularly during wintertime at high (or low) latitude.

    Vitamin D deficiency contributes to the development of nutritional rickets in children and osteomalacia in adults, both seriously debilitating conditions that are completely preventable with an adequate dietary supply of vitamin D and calcium. Regardless of which international recommended intake is selected, the current supply of vitamin D in commonly consumed foods makes it unfeasible for most people to meet their dietary requirements for vitamin D without supplementation.

    Emerging scientific evidence from the EC-funded ODIN project suggests that many foods, including fish, eggs, meats as well as dairy products could be part of a public health strategy for vitamin D deficiency prevention in the population. This would positively impact public health in a cost-effective and inclusive way.

    While most European countries are impacted by suboptimal vitamin D status, Finland is the exception. In 2003, the country introduced a national regulation which includes mandatory fortification of milk and margarine spreads. The population has now achieved a vitamin D status of 75nmol/L. Recently, the Swedish National Food Agency (NFA) proposed to introduce a similar regulation that will go a step further by extending the products subject to mandatory vitamin D fortification.


    *This information is solely for scientific informational purposes only and not intended for marketing and/or sales claims purposes.
  • The new EPA METHOD 325 for sampling Volatile Organic Compounds from Fugitive and Area Sources was promulgated in September of 2015. The petroleum refineries have 2 years to comply with the new ruling. Benzene emissions are the focus of the new ruling, but other VOC’s can be monitored using the same sampling tube. The air samples are collected using thermal desorption tubes that are deployed along fenceline of the property and remain deployed for 14 days. The samples are collected passively, without the using of an air sampling pump. After sampling the diffusive endcap is replaced with a metal storage cap and sent to a laboratory where they’re analyzed by thermal desorption gas chromatography. This is the first of a two series presentation that focuses on the analysis side of the workflow. It provides users the steps required to comply with the new EPA fence line regulations and what is needed to optimize the method for high sample throughput. Refineries and testing laboratories will benefit by gaining valuable information on the optimum techniques to perform this method and what it takes to comply. An introduction to the theory and operation of thermal desorption will also be included.
  • Scopus features comprehensive, up-to-date, unbiased & reliable content. In this webinar we will walk you through our content selection process, curation programs, expansion programs, the impact of metrics, what is to come in 2016 and some fun tips and tricks on how you can get the most out of the Scopus content. You will find out why Scopus gives you the most complete picture of what is going on in the world of research.
  • The healthcare industry is fundamentally influenced by the deployment of technology. More than any other industry, healthcare can benefit from the adoption, and Africa is uniquely positioned to gain from the advances. The audience will receive the following advantages by attending the presentation:

    • Frost & Sullivan will share top predictions for the healthcare industry in Africa for 2016
    • Learn about key trends in the African healthcare industry
    • Uncover areas of opportunity in healthcare
    • Participate in an interactive Q&A session
  • According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

    As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous. As important as what we are saying and where these conversations are taking place may be, it is only part of the conundrum. Developing, maintaining and managing content is a continuous challenge, made all the more taxing not only by strict internal deadlines but the cultural, linguistic and regulatory challenges that go hand in hand with managing global communications.

    Working with our expert partner SDL , we present a live webinar which will deliver insight and guidance on this topic, look in depth at one of the more traditional areas of patient liaison – trial recruitment – and bring you advice from the ‘frontline’ on what works in tackling these content challenges.

    On this latest live webinar, we’ll be discussing:
    •How to develop patient-centric recruitment content that REALLY communicates
    •Best practices of how to handle the linguistic, cultural and regulatory challenges often faced with creating multilingual patient-centric content
    •How simple content management best practices can help you become more patient centric with your content
    •Recent case studies: we’ll be discussing recent successes of global pharmaceutical businesses that have optimised and streamlined recruitment processes with relevant, accurate content development in the right language.
  • Personalized healthcare continues to evolve. There are now five pillars of cancer therapy and two of the five, targeted therapies and immunotherapy, are personalized approaches. Join us at 9 AM MST, February 25, 2016 as Eric Walk MD, FCAP, Chief Medical Officer, Ventana Medical Systems, Inc. (Ventana), addresses how personalized healthcare has evolved and impacted cancer diagnosis and therapy.
  • Filtration, although a common practice in many types of laboratories, is a critical step in many processes including medium and buffer preparation, sample clarification, removal of microbial contaminants, concentration and inline filtration of gases to name a few. Choosing the correct filter is contingent on the application, the material(s) to be filtered and other factors which must be considered when choosing the product for use in one’s process. This webinar will focus on:

    An Introduction to Filtration:
    • Basic principles of filtration
    • Overview of membranes
    • Overview of formats

    Choosing the Correct Filtration Product for your Application:
    • Sterilization
    • Clarification of solutions
    • Ultracentrifugation
  • This webinar will highlight some of the contributions recently published in the British Ecological Society journals Special Feature entitled "Demography Beyond the Population". This Special Feature was a collaborative effort including articles in all six BES journals. This is the first time such a large ecological collaboration has been attempted worldwide. This cross-journal approach has allowed us to highlight the strongly interdisciplinary nature of the field of demography to its fullest potential as well as to lay down the foundations for future directions at the interface of ecology, evolution, conservation biology and human welfare. The webinar has several international speakers and will discuss the articles in the Special Feature and the implications for demography research going forward.
  • •Are you looking to deliver your research within Europe?
    •Do you need multiple, reliable sites and experienced investigators?
    •Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed with the Department of Health’s investment in the clinical research network infrastructure in the UK.

    Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we can help.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Dr Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for running clinical research studies.

    You can discover:
    •How much the UK’s market volume of commercial contract research has grown and how we recruited over 34,000 patients to commercial clinical trials in 2014/15
    •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    •The free feasibility service run by the NIHR CRN
    •How to gain access to our experienced clinical experts
    •How we are keeping clinical research in the public eye
    •How the UK is sharpening its competitive edge by achieving more key first global patients

    The NIHR CRN is exhibiting at the BioPharma Asia Convention 2016, visit stand B19 from 22-24 March to find out more about what we do to support clinical research and how we can help you deliver your studies in the UK.
  • Physical chemistry and microengineering techniques are ever more important to tools in the medical and pharmaceutical industries, as well as fundamental biological and biochemical research. In this webinar we will discuss modelling techniques for analysing microfluidics, multiphase flows, heat and mass transfer, enzyme-catalysed reactions, and amperometric sensing techniques. We will focus on the use of these modelling methods for designing biosensors, bioreactors, and biological “lab-on-a-chip” devices. The webinar will include a modelling demonstration and a Q&A session.
  • This webinar will focus on how to personalize your Scopus experience and make your search more effective. We will also spend a significant portion of the time on basic search and how you can use it to be more efficient in your research.
  • Colorectal cancer is the third most commonly diagnosed cancer in men and women, and is the second leading over all cause of cancer deaths in the United States. Each year, the CDC reports that approximately 135,000 people are diagnosed with colorectal cancer, and over 50,000 succumb each year to the illness. The National Cancer Institute cites a decline in the mortality rate of colorectal cancer due to advanced screening and early diagnosis. Immunohistochemistry has served as the catalyst for these advancements in colorectal cancer diagnosis. This presentation covers many of the basic science, facts, and statistics of colorectal cancer, as well as the utility of immunohistochemical testing with markers such as cadherin¬17, CDX¬2, SATB2, and the mismatch repair proteins in the accurate diagnosis and survival rates of colorectal cancer.
  • This webinar will provide you with an overview how digital can be integrated into medical plans and what it takes to deliver multichannel medical excellence at launch.

    Key topics include:
    •Overview of typical launch categories and their key communication drivers and multichannel opportunities
    •The 4 main pre-launch stakeholders and how to integrate digital initiatives in a balanced medical mix whilst respecting legal and regulatory guidelines
    oeKOLs: Gathering insight and engagement planning
    oeHCPs: Channel selection to ensure immersive learning and education
    oePatients: Gathering treatment insight and prepare education & value-focused “beyond the-pill” strategies for launch
    oePayers: Establish value
    •Assess the clinical impact of e-medical programmes and how to create KPIs and dashboards to assess the success of your cross-channel activities
    •Prepare your organization for emedical excellence through multichannel skills development and enablement for MSLs and internal staff